- Home
- CPRX vs CERT Comparison
CPRX vs CERT Comparison
Compare CPRX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- CERT
- Stock Information
- Founded
- CPRX 2002
- CERT 2008
- Country
- CPRX United States
- CERT United States
- Employees
- CPRX N/A
- CERT N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- CPRX Health Care
- CERT Technology
- Exchange
- CPRX Nasdaq
- CERT Nasdaq
- Market Cap
- CPRX 2.9B
- CERT 2.3B
- IPO Year
- CPRX 2006
- CERT 2020
- Fundamental
- Price
- CPRX $23.37
- CERT $11.98
- Analyst Decision
- CPRX Strong Buy
- CERT Buy
- Analyst Count
- CPRX 7
- CERT 6
- Target Price
- CPRX $32.29
- CERT $15.60
- AVG Volume (30 Days)
- CPRX 975.9K
- CERT 2.8M
- Earning Date
- CPRX 05-07-2025
- CERT 05-05-2025
- Dividend Yield
- CPRX N/A
- CERT N/A
- EPS Growth
- CPRX 178.13
- CERT N/A
- EPS
- CPRX 1.57
- CERT N/A
- Revenue
- CPRX $534,645,999.00
- CERT $394,498,000.00
- Revenue This Year
- CPRX $15.59
- CERT $11.41
- Revenue Next Year
- CPRX $8.90
- CERT $8.78
- P/E Ratio
- CPRX $14.90
- CERT N/A
- Revenue Growth
- CPRX 29.97
- CERT 9.37
- 52 Week Low
- CPRX $14.47
- CERT $8.64
- 52 Week High
- CPRX $26.16
- CERT $17.94
- Technical
- Relative Strength Index (RSI)
- CPRX 50.33
- CERT 45.14
- Support Level
- CPRX $20.80
- CERT $11.22
- Resistance Level
- CPRX $25.01
- CERT $12.30
- Average True Range (ATR)
- CPRX 0.83
- CERT 0.68
- MACD
- CPRX -0.06
- CERT -0.32
- Stochastic Oscillator
- CPRX 61.05
- CERT 18.37
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.